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Background. Rosai-Dorfmann disease (RDD) is a rare, idiopathic non-Langerhans cell histiocytosis, affecting children and
young adults, that commonly presents as painless, massive cervical lymphadenopathy with fever, weight loss, and polyclonal
hypergammaglobulinemia. Cervical lymphadenopathy and extranodal involvement are the main presentations. On the contrary,
ophthalmic involvement and localisation in the central nervous system are rare. Case Report. An old man was admitted to our
hospital for first seizure. Brain imaging studies revealed on the left an extra-axial thickening of the dura mater with enhancement
and perilesional oedema, infiltrating the sphenoorbital fissure and an isointense mass with enhancement in the orbital region with
dislocation of the optic nerve. Pathological and immunohistochemistry examination of the bioptical specimen was consistent with
a diagnosis of RDD. Treatment with levetiracetam and steroids was started obtaining only remission of seizures. Because of the
patient refusal of the surgical debulking, therapy with mercaptopurine was started, stopping disease progression. Conclusion. So
far, very few cases of extranodal RDD with multiple CNS lesions involving the orbital region have been described. Our case is
significant because it is the first case in which the efficacy of mercaptopurine treatment has been documented in an adult patient
with isolated ocular and intracranial RDD.
1. Introduction
Rosai-Dorfmann disease (RDD) is a rare idiopathic non-
Langerhans cell histiocytosis, of unknown aetiology com-
monly presenting as painless, massive cervical lymphade-
nopathy with fever, weight loss, and polyclonal hypergamma-
globulinemia. The disease mainly affects children and young
adults [1, 2]. Over 90% of patients present with cervical lym-
phadenopathy. Extranodal involvement occurs in 40% of
cases with anatomic distribution that include paranasal
sinuses, respiratory tract, skin, nose, and bone. Ophthalmic
involvement is seen in 10% of cases [3]. These include eyelid
and orbital mass and rarely uveitis. Rosai-Dorfmann dis-
ease could mimic lymphoma, histiocytic and lacrimal gland
tumours [3–7]. Localisation in the central nervous system
(CNS) is rare (4% of cases) [8, 9]. Various treatments have
been proposed, including steroid therapy, chemotherapeutic
regimens, radiotherapy, surgery, and combinations of the
above but optimal treatment has yet to be established.
2. Case Report
A 70-year-old man, with history of hypertension, presented
an abrupt onset of tremor and jerking of his right arm and,
after two days, he was admitted to our hospital for a critical
sudden episode with secondary generalization with loss of
consciousness, followed by amnesia about the event. For few
months, he has been conscious of reduced vision and foreign
body sensation in his left eye. He also complained of dizzi-
ness, clumsiness, and paraesthesia in his right arm especially
while using little objects and playing the piano. His family
history was positive for tumours. When he was five years old,
his right eye was enucleated because of an eye infection and,
since then, he carries a prosthetic eye. He had a moderate
low vision (20/160) in his left eye. Neurological examination
showed distal weakness in his right arm. Brain CT scan
showed slight hyperdensity in the left frontoparietal region,
suggesting a tumour. Brain and orbit MRI revealed in left
frontoparietal-temporal region extra-axial thickening of the
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duramater with enhancement and perilesional oedema, infil-
trating the sphenoorbital fissure, and an isointense mass
with enhancement in the orbital region with dislocation of
the optic nerve, which was thought to be consistent with a
meningioma (Figures 1(a) and 1(b)). EEG shows diffuse slow-
ing with excessive delta and theta activity. Blood examina-
tion was normal, except for hyperlipidemia and mild eleva-
tion of erythrocyte sedimentation rate. The patient under-
went surgery to perform cerebral biopsy. Histopathological
evaluation of the surgical piece revealed a fibrotic tissue
with a histiocytic reaction and a large number of histiocytes
containing normal-appearing lymphocytes within their cyto-
plasm (emperipolesis). Immunohistochemistry was positive
for S-100 protein and CD68 leucocyte antigens and negative
for CD1a. According to published criteria, these findings
were consistent with a diagnosis of Rosai-Dorfman disease.
The patient refused the surgical debulking to salvage his
vision. Treatment with levetiracetam (500mg twice a day)
and steroid (Dexamethasone 4 mg intravenously once a day)
was startedwith remission of critical symptoms.MRI features
showed a decreased of edema but no modification of the
lesions previously reported.
Three months later, a therapy with mercaptopurine was
startedwith a daily dosage of 2,5mg/kg, and steroid treatment
was stopped. One year later, MRI showed slight reduction
of the parietal-temporal lesion (Figures 1(c) and 1(d)), and
levetiracetam therapy was stopped. At his one-year follow-up
appointment, the patient reported no seizure activity without
further loss of vision. The third brain MRI, performed
approximately two years after diagnosis, showed a further
reduction of the parietal-temporal lesion and of the left
intra-orbital mass that enhanced uniformly after gadolinium
administration (Figures 1(e) and 1(f)).
3. Discussion
Sinus histiocytosis with massive lymphadenopathy was orig-
inally described by Rosai and Dorfman in 1969 [1]. This is
a rare non-Langerhans histiocytosis of unknown aetiology
that usually presents with painless bilateral cervical lympha-
denopathy, fever, anemia, leukocytosis, an elevated erythro-
cyte sedimentation rate, and polyclonal hypergammaglob-
ulinemia. The ophthalmic involvement of Rosai-Dorfman
disease include eyelid, orbital, and lacrimal gland manifes-
tations and uveitis. Orbital involvement is the most common
of ophthalmic manifestations [3–6]. Recently, also a case of
compressive neuropathy of the optic nerve (with consecutive
gradual vision loss) due to a RDD mass in ethmoid and
sphenoid sinus extending into suprasellar region and causing
bone erosion has been described [7].
Involvement of the central nervous system is rare [8,
9] and it occurs generally in middle-aged men (mean 39,4
years) causing headaches, seizure, visual symptoms, and focal
deficits [9–12]. Involvement of the spinal cord has also been
described [13, 14]. The disease is frequently reported in
leptomeninges and it typically presents as ameningioma-like,
extra-parenchymal, dural-based mass, similar, on MRI, to
meningioma histiocytosis X lymphoproliferative disorders,
plasma cell granulomas, and infectious disease [15, 16]. Nev-
ertheless, there are also cases of isolated CNS presentation
without dural involvement [17].
Histological and immunophenotypic assays are useful in
establishing the diagnosis. In fact, RDD is characterized by
abundant sheets of large andmedium sized vacuolated histio-
cytes in a fibrous stroma, interspersed with foci of chronic
inflammatory cells. In addition, the presence of emperipolesis
is a hallmark of the disease, even if this may be less marked
in intracranial disease [18]. In RDD, the histiocytes typically
stain positive for S100 and CD68 and negative for CD1a
[18–21]. These features with the absence of eosinophils and
Birbeck’s granules on electronmicroscopymake the differen-
tial diagnosis with CNS Langerhans Cell Histiocytosis (LCH)
possible [18, 22, 23]. Another interesting differential diagnosis
is Erdheim-Cester Disease (ECD), which is a rare non-
Langerhans histiocytic disorder most commonly character-
ized by multifocal osteosclerotic lesions of the long bones.
Neurologic involvement (mainly periorbital) is seen in 40 to
50 percent of cases. Biopsies of involved tissues are charac-
terized by tissue infiltration by foamy (xanthomatous) his-
tiocytes with interspersed inflammatory cells, multinucleate
giant cells (Touton cells), and admixed or surrounding fibro-
sis. ECD cells express the histiocyte marker CD68, CD163,
and Factor XIIIa but unlike Langerhans cell histiocytosis
do not express CD1a or S100. Birbeck granules are absent
(http://www.uptodate.com/).
In our case, the findings of emperipolesis, positivity for
CD68 and S100 and negativity for CD1a were coherent with
the diagnosis of RDD.
Most patients experience a course of spontaneous exacer-
bations and remissions [15]. However, if in 50% of systemic
cases the disease will resolve spontaneously, a small per-
centage of patients (17%) will have asymptomatic persistent
adenopathy and some will have residual symptoms for 5 to 10
years after onset [15]. Even if the course of intracranial lesions
of RDD is generally considered to be benign, no spontaneous
regression has been reported [1, 14]. Rarely intracranial RDD
has an aggressive course [14].
Although a variety of treatments have been proposed [11,
13, 24], for the rare primary orbital and intracranial RDDonly
surgical resection, radical if possible, is considered the opti-
mal treatment [25–27]. When this approach is not possible,
according to the literature, roentgen therapy, chemotherapy,
steroid therapy [11, 28], rituximab [29], interferon-alfa-2a
[30], and immunosuppressive agents, such as azathioprine,
methotrexate, and mercaptopurine [31–33], can be used.
Alqanatish et al. described a case of a 7-year-old childwith
concomitant LES and RDD, who was treated with rutiximab
(500mg/m2/dose), with complete remission of the massive
lymphadenopathy after 7 weeks of treatment [29]. Also high
dose of interferon-alfa-2a, in particular, the pegylated form,
has shown dramatic efficacy in cases of systemic RDD [30].
Nevertheless, it should be avoided because it could favour
the occurrence of seizures [31]. Other options include immu-
nosuppressive agents, such as azathioprine. Le Guenno et al.
described a 57-year-old man with a history of diseases
that involve the monocyte/macrophage system (Q fever
and Crohn disease) who developed also RDD and was




Figure 1: Axial (a, c, e) and coronal (b, d, f) enhanced T1 MR images reveal enhancing masses along the left frontoparietal-temporal region
and the orbital region with dislocation of the optic nerve at onset (a, b) and in one-year (c, d) and two-year (e, f) follow-up, respectively.
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successfully treated with azathioprine [32]. Moreover, two
children showed a sustained response to a combination of
methotrexate and mercaptopurine [33, 34]. Another two
paediatric cases with nonintracranial involvement showed
a good response to chemotherapy with vinblastine, predni-
sone, 6-mercaptopurine andmethotrexate [35], and 2-chloro-
deoxyadenosine (2-CdA, cladribine) [36].
Like a minority of patients with concurrent orbital and
neurological manifestations as the sole extranodal site of
involvement without synchronous nodal disease, surgery
could have represented the best therapy for our patient;
unfortunately, he refused this option. Therefore, considering
the failure of conventional approach with steroid therapy, a
treatment with mercaptopurine was started. This is a purine
antagonist, which inhibits DNA and RNA synthesis acting
as a false metabolite. The treatment caused a stabilization of
the lesions and after 24 months, no adverse event has been
reported including anemia, granulocytopenia, haemorrhage,
lymphocytopenia, and leukopenia. Although spontaneous
remissions are not uncommon and surgical resection appears
to be the most efficacious approach, therapy with mercapto-
purine in our patient led to stopping of the disease progres-
sion. To our knowledge, considering that the other reported
cases are paediatric [33–36], this is the first reported case
of an adult patient with isolated ocular and intracranial
RDD in which the efficacy of mercaptopurine treatment has
been documented. In this way, our case supports the use of
purine antagonists and purine antimetabolite for an effica-
cious treatment of adult forms of RDD.
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